On May 26, 2020 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that management will host investor conference calls through June (Press release, Autolus, MAY 26, 2020, View Source [SID1234558475]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1 June 2020 – Dr. Christian Itin, chairman and chief executive officer, along with the AUTO3 clinical team, will host an investor call and webcast at 8.30 am EDT, 1.30 pm BST to discuss presentations related to its AUTO3 program, the company’s CAR T cell therapy being investigated in the Alexander study, a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during the Annual Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program. After the conference call, a replay will be available for one week.

4 June 2020 – Dr. Christian Itin, chairman and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8.30 am EDT, 1.30 pm BST and will also host virtual one-on-one meetings. A live audio webcast of the fireside chat will be available on the investor relations section of Autolus’ website at View Source An archived replay will be available on the company’s website for a period of 90 days after the conference.

10 June 2020 – Dr. Christian Itin, chairman and chief executive officer, will participate in a fireside chat at the Goldman Sachs Healthcare Conference at 09.40 am EDT, 2.40 pm BST on 10 June. A live audio webcast of the fireside chat will be available on the investor relations section of Autolus’ website at View Source An archived replay will be available on the company’s website for a period of 90 days after the conference.
15 June 2020 – Dr. Christian Itin, chairman and chief executive officer, along with the AUTO1 and AUTO3 clinical teams, will host an investor call and webcast at 8.30 am EDT, 1.30 pm BST to discuss presentations related to its AUTO1 and AUTO3 programs, the company’s CAR T cell therapies being investigated in Phase 1/2 studies of adult Acute Lymphocytic Leukemia (ALL) and relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL), respectively, at the European Hematology Association (EHA) (Free EHA Whitepaper) EHA (Free EHA Whitepaper)25 Virtual Congress on June 11 – 14, 2020. After the conference call, a replay will be available for one week.

25 June 2020 – Dr. Christian Itin, chairman and chief executive officer, along with the AUTO5, AUTO6NG and AUTO7 clinical teams, will host an investor call and webcast at 8.30 am EDT, 1.30 pm BST to discuss presentations related to its next-generation programmed T cell therapies in T cell lymphoma, small cell lung cancer and prostate cancer, respectively, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II on Jun 22 – 24, 2020. After the conference call, a replay will be available for one week.